Serum markers of bone turnover of patients and controls
Serum marker . | MM patients median (range) . | Controls median (range) . | P . |
|---|---|---|---|
| sRANKL, pM | 7.06 (0.88-41.94) | 2.66 (0.81-4.73) | <.0001 |
| OPG, pM | 4.71 (0.31-16.66) | 7.98 (7.77-8.54) | .007 |
| sRANKL/OPG ratio | 1.58 (0.10-44.04) | 0.33 (0.10-0.59) | <.0001 |
| Osteoclastic activity markers | |||
| NTX (nM BCE/mM creatinine) | 132 (25-571) | 37.9 (11-76.2) | <.0001 |
| TRACP-5b (U/L) | 6.57 (1.32-47.12) | 3.11 (1-5) | <.0001 |
| Osteoblastic activity markers | |||
| bALP (U/L) | 43.1 (12-98.4) | 93.9 (45.3-124) | .01 |
| OC (ng/mL) | 16.0 (1-52) | 37 (25-52.8) | <.0001 |
Serum marker . | MM patients median (range) . | Controls median (range) . | P . |
|---|---|---|---|
| sRANKL, pM | 7.06 (0.88-41.94) | 2.66 (0.81-4.73) | <.0001 |
| OPG, pM | 4.71 (0.31-16.66) | 7.98 (7.77-8.54) | .007 |
| sRANKL/OPG ratio | 1.58 (0.10-44.04) | 0.33 (0.10-0.59) | <.0001 |
| Osteoclastic activity markers | |||
| NTX (nM BCE/mM creatinine) | 132 (25-571) | 37.9 (11-76.2) | <.0001 |
| TRACP-5b (U/L) | 6.57 (1.32-47.12) | 3.11 (1-5) | <.0001 |
| Osteoblastic activity markers | |||
| bALP (U/L) | 43.1 (12-98.4) | 93.9 (45.3-124) | .01 |
| OC (ng/mL) | 16.0 (1-52) | 37 (25-52.8) | <.0001 |